Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson’s disease

Ever since its introduction 40 years ago l-3,4-dihydroxyphenylalanine (l-DOPA) therapy has retained its role as the leading standard medication for patients with Parkinson’s disease. With time, however, the shortcomings of oral l-DOPA treatment have become apparent, particularly the motor fluctuatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblad, Carl, Li, Qin, Pioli, Elsa Y., Dovero, Sandra, Antunes, André SLM, Agúndez, Leticia, Bardelli, Martino, Linden, R. Michael, Henckaerts, Els, Björklund, Anders, Bezard, Erwan, Björklund, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658866/
https://www.ncbi.nlm.nih.gov/pubmed/31243443
http://dx.doi.org/10.1093/brain/awz176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658866/
https://www.ncbi.nlm.nih.gov/pubmed/31243443
http://dx.doi.org/10.1093/brain/awz176

Ejemplares similares